Age-associated cognitive decline amongst otherwise healthy older individuals is a multifaceted characteristic of ageing. The role of oxidative stress biomarkers has been increasingly examined in the context of pathological aging conditions that affect cognition. retaining and retrieving verbal information in episodic memory). This is, to our knowledge, the first report of compromised verbal episodic memory in healthy ageing humans being linked to increased levels of F2-Isoprostanes. These results have relevance for interventions aimed at improving cognitive performance in the healthy elderly.
INTRODUCTION
Normal ageing is associated with a gradual and variable rate of decline of mental functions and cognitive processes (Bishop, Lu, & Yankner, 2010) . This decline in cognitive abilities affects attention, speed of information processing, as well as specific aspects of memory and intelligence (Simen, Bordner, Martin, Moy, & Barry, 2011). The biological mechanisms underpinning this decrease in cognitive ability are yet to be completely understood. Processes such as oxidative stress, can accelerate the ageing process. Oxidative damage affects phospholipids, proteins and nucleic acids, and is considered a major contributor to pathological ageing, co-occurring cognitive decline, and age related cognitive decline Prolific metabolic activity within cellular mitochondria produces unstable endogenous oxygen radicals called reactive oxygen species (ROS) or free radicals as a result of cellular respiration, which over time causes cumulative damage to cell components (Floyd, 1999; Harman, 2003; Rahman, 2007) . Under normal conditions, an endogenous antioxidant system such as superoxide dismutase (SOD) catalyses superoxide radicals and reduces their harmful affect into oxygen and hydrogen peroxide which are less harmful than the original radical state (Pauling, 1979) . A different endogenous antioxidant, Catalase (CAT), then reduces hydrogen peroxide into water and oxygen. This occurs to maintain beneficial levels of ROS and prevent damage to molecular bonds, cell membranes and DNA (Basu, 2010 ). An imbalance between the oxidant scavenging systems, antioxidant defence mechanism and ROS levels, in favour of the latter, results in oxidative stress. Oxidative stress produces Therefore, the purpose of the current study was to examine the influence of oxidative phospholipid concentrations as measured in vivo by plasma F2-Isoprostanes on cognitive performance, measured using the CDR battery, in a group of healthy adults without diagnosed cardiovascular, neurological or psychiatric illness. It was hypothesised that higher F2-Isoprostane concentrations would be associated with poorer cognitive performance scores across the cognitive tasks.
MATERIALS AND METHOD

Participants
The sample comprised 211 healthy volunteers (Male; 88: Female 123) aged 60 -75years from the Australian Research Council Longevity Intervention (ARCLI) study cohort (Stough, et al., 2012) . The data for this analysis was drawn from baseline data from the ARCLI study (a 7 large intervention study aimed at examining the effects of two natural supplements on cognitive performance). For the purpose of this sub-study, the participants were divided into two groups (low and high F2-Isoprostanes), defined through a median split of F2-Isoprostanes (occurring at 932pmol/L: see Figure 1 ); the demographics of the two groups appear in Table   1 .
Participant Recruitment
Participants were recruited through radio, newspaper articles as well as poster and flyer distribution. Participants were excluded if they were taking cognitive enhancing supplements (e.g. Ginkgo biloba), were current smokers, had a history of drug and/or alcohol abuse or taking prescribed antidepressant, anxiolytic or antipsychotic medication. Participants were eligible if they did not have a diagnosis of diabetes, dementia, neurological or psychiatric disorder or cardiovascular disease. Eligibility also included not having a recent history (defined as a period longer than 6 weeks, over the past 5 years), of a chronic or severe illness.
Eligibility was initially determined from telephone screening by an experienced research assistant relying on the interested participants' self-report. During a face-to-face interview, general demographic information was collected and, further eligibility screening was Table 2 .
Memory and Cognition Screening Tools
The is commonly used to screen for dementia. The MMSE evaluates six areas of cognitive function: orientation, attention, immediate recall, short-term recall, language, and the ability to follow simple verbal and written commands.
Self-reported Memory Complaints
In addition to the MMSE screening tool, participants were asked "Do you have problems with your memory?".
General intelligence (IQ)
Two tests from the Wechsler Abbreviated Scale of Intelligence (WASI) were administered to all participants to provide an IQ estimate. Participants completed the vocabulary and matrix reasoning subsets of the WASI. The vocabulary subtest is a 42-itemtask, which requires the examinee to orally define words that are presented visually and orally. The matrix reasoning subtest shows a series of 35 incomplete grid patterns, which the examinee is asked to complete by pointing to, or stating, the correct pattern from five possible choices. The WASI is a reliable measure of intelligence for use in clinical and research settings.
Geriatric Depression Scale (GDS)
The GDS (Yesavage et al. 1982 ) is a basic screening measure for depression suitable for elderly populations. Although the GDS cannot be used to diagnose clinical depression it provides insight into the severity of depressive symptoms experienced by the rater. The GDS sums 30 questions each of which are answered "yes" or "no". A total score of 0-9 is considered normal, a score of 10-19 indicates mild depressive symptoms and a score of [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] indicates severe depressive symptoms.
Biochemical Measure: F2-Isoprostanes
Plasma concentrations of F2-Isoprostanes were collected as the measurement of oxidative stress in the current study, with the levels of 8-iso-PGF2a being quantified by gas chromatograph mass spectroscopy (GC-MS). Blood samples were collected from the forearm of each participant via the cephalic vein by a registered nurse or qualified phlebotomist into a 10mL vial containing ethylenediaminetetraacetic acid and then centrifuged at 3000 x g for 10 minutes at 4°C. To protect the samples from oxidation, 10µl of butylated hydroxytoluene was added to the vials prior to storage at -80°C at Swinburne University of Technology. Frozen samples were shipped to the University of Western Australia where they were quantified for F2-Isoprostanes using a standard assay kit and employing negative ion chemical ionisation- F2-isoprostanes were detected by selected ion monitoring using m/z 569 and m/z 573 for endogenous and tetra-deuterated internal standards, respectively.
GC-MS as described by Mori and colleagues (1999
Procedure
Participants attended Swinburne University of Technology in Melbourne for two sessions with the visits being up to a week apart. Eligible participants could attend during the morning or afternoon with the allocated time of day remaining consistent, minimizing confounding effects of fatigue and diurnal variation on cognitive and blood parameters.
Morning participants attended after fasting overnight while afternoon participants were able to consume a light breakfast and lunch. At the beginning of the first visit, participants provided written and informed consent prior to engaging in any screening questionnaires or undergoing blood tests or cognitive test batteries. Participants were screened for depressive symptoms and any possible memory impairments using the GDS and the MMSE, respectively. Current intellectual status was assessed using the WASI. General demographic information was also collected such as; age, gender and BMI. Participants completed a preliminary run through of the cognitive tasks. Blood samples were collected at the second visit, prior to participants completing the cognitive test batteries already described.
Statistical Analysis
All analyses were conducted using the SAS statistical package Version 9. 
RESULTS
The median split (932pmol/L) of the participants resulted in "Low" and "High" groupings based upon F2-Isoprostane levels (F2-Isoprostane levels: Low group, M = 721.33pmol/L, SD = 120.11; High group, M = 1466.97pmol/L, SD = 527.86). Table 1 shows that the groups were well matched on age, MMSE scores, years of education and reported memory problems.
Interestingly, the High F2-Isoprostane group reported marginally (half a point) higher levels of depression. There was a notable imbalance in both groups for gender, with females being overly represented. Expected associations between task performance and the proposed covariates of age and years of education also confirmed the rationale for including them as covariates. The level of task performance on the individual CDR tasks were broadly consistent with the norms generated for the CDR System (Wesnes, McNamara & Annas, 2016).
"Insert Table 1" The results concerning the influence of F2-Isoprostane levels on cognitive performance are presented in Table 2 . The Quality of Episodic Memory factor score and the Immediate and Delayed Recall measures (number of words recalled) showed a significant main effect of F2-Isoprostane group.
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"Insert Table 2" Significant differences between the low F2-isoprostane and high F2-isoprostane groups were noted for the Factor Score; Quality of Episodic Memory [F (1, 194 
DISCUSSION
Our results indicate that otherwise healthy older adults who present with lower F2-Isoprostane levels are superior in retaining information in episodic memory, compared to those older adults with relatively raised F2-Isoprostane levels. The effect sizes for these differences in episodic memory and verbal recall were in the small to medium range (Cohen, 1988) , bordering on what is considered 'clinically significant' (Harvey, 2012). To our knowledge, this is the first report of impaired episodic memory and verbal recall in healthy older adults, which highlights the value of F2-Isoprostanes as a biomarker that could be used to predict cognitive change in non-demented older adults. All participants age, gender, depression scores and years of education were controlled for in these analyses, and no significant differences were observed in the measures of attention, or the speed at which information was 
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As our data is drawn from a baseline too, we can only speculate whether the relationship observed between episodic memory performance would remain significant over the course of the ageing process. We can, however, highlight the necessity in utilising highly sensitive measures of cognitive performance to map cognitive capacity in carefully selected human populations. Measure such as the MMSE, or modified versions (e.g., Modified Mini-Mental State Examination: 3MS), are sufficient for use as screening tools, or to classify groups (e.g., mild cognitive impairment versus severe cognitive impairment as seen in demented patients), rather than as a criterion variable, as it is relatively insensitive to changes to specific aspects of cognition. Notably MMSE did not differ between our high and low F2-Isoprostane groups.
In conclusion, the present study identified that lower plasma levels of F2-Isoprostanes are 
